Article · 27 May 2026
ArticlePublished 13 Nov 2020
Empagliflozin in patients with heart failure and reduced ejection fraction
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Sodium–Glucose Cotransporter 2 (SGLT2) inhibitors reduce the risk of a first hospitalization for heart failure in type 2 diabetics. But data regarding role of SGLT2 inhibitors in HFrEF is limited. Methods: In this prospective small centre trial, we randomly assigned 822 patients in class II, III, NYHA and an ejection fraction of 35% or less to receive either empagliflozin or placebo, in addition to optimal medical therapy. The primary outcome was a composite of worsening heart failure or cardiovascular death. Results: Over a period of 24months, the primary outcome occurred in 61 of 411 patients (14.8%) in the empagliflozin group and in 94 of 411 patients (22.9%) in the placebo group (hazard ratio, 0.65; 95% confidence interval [CI], 0.48 to 0.87; P 0.003). Of the patients receiving empagliflozin, 40 (9.7%) were hospitalized for heart failure, as compared with 60 patients (14.6%) receiving placebo (hazard ratio, 0.67; 95% CI, 0.46 to 0.97). Cardiovascular deaths occurred in 19 patients (4.6%) who received empagliflozin and in 26 (6.3%) who received placebo(hazardratio, 0.73; 95% CI, 0.41 to 1.30). A total of 36 patients (8.75%) in the empagliflozin group and 49 patients (11.9%) in the placebo group died from any cause (hazardratio, 0.97; 95% CI, 0.97 to 1.30). Conclusion: In patients with heart failure and a reduced ejection fraction, the risk of cardiovascular death and heart failure is lower among those who received empagliflozin compared to placebo, irrespective of their diabetic status.
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Interventional Cardiology.
Article · 24 Mar 2026
Redo arteriovenous fistula in end stage kidney disease: Risk factors and outcomes in Taiz – Yemen
Article · 23 Feb 2026
The Silent Giant : Incidental Discovery of a Large Left Atrial Myxoma
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInterventional Cardiology
- SubjectCardiology
- BylineArticles whose byline prints “Naveen Jamwal”
- BylineArticles whose byline prints “S. S. Tripathi”
- BylineArticles whose byline prints “Malvika Misra”